Research Dynamics enters CRO service agreement

By Wai Lang Chu

- Last updated on GMT

Related tags Clinical trial

Research Dynamics have struck a deal with VirtualScopics in which
they have signed a non-exclusive partnership agreement to co-market
their clinical research services and technologies.

The deal gives Research Dynamics the necessary springboard as a technology CRO, to bring cost savings to sponsors for clinical trials. Financial terms of the deal were not disclosed.

Research Dynamics​ provides management services for clinical trials, specifically in the areas of Oncology, MS and Alzheimer Disease, which will now have the option of utilising VirtualScopics' biomarker imaging technology.

VirtualScopics​' algorithms enable three-dimensional registration, fusion, hard and soft tissue identification, anatomically guided segmentation and feature extraction.

Sponsors can determine the efficacy of a compound earlier in the clinical trial process.

In addition, an improvement in image analysis throughput is possible by eliminating "reader" bottleneck via automation.

Sample size requirements can be reduced through increased precision while a compressed trial time yields longer patent protected revenue streams.

These applications comply with applicable regulatory requirements (CFR21 Pt. 11) for FDA-facing trials, or can be designed specifically for a particular study per sponsor requirements.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us